We are pleased to announce that on 30 November 2020 Quadrum Investment Fund III acquired an interest in Rockmed Pharma. The participation in Rockmed Pharma will enable the company to accelerate its international growth ambitions. Over the past few years Rockmed Pharma has seen a steady development and, under the leadership of CEO Bas Rockx, a solid foundation has been formed.

Quadrum Capital is already positioned in the pharmaceutical field with its portfolio company Ace Pharmaceuticals in Zeewolde.

About Rockmed Pharma

Rockmed Pharma was founded in 2013 and is a supplier of ophthalmic medicines and medical devices. The company is a carve-out of Rockmed Group, the leading independent ophthalmic player in the Benelux.

Rockmed Pharma focuses on niches within the ophthalmic market. Customers are large pharmaceutical wholesalers, hospitals and private clinics. From its head office in Oirschot, Rockmed Pharma has a substantial market share of the Dutch and Belgian ophthalmic market through a large (inter)national network of ophthalmologists. Rockmed Pharma's commercial strength is recognised by its competitors and, in addition to the supply of ophthalmic medicines and medical devices, the company also provides promotional services.

In recent years Rockmed Pharma has strongly focused on obtaining its own registrations. Under the umbrella of Quadrum Capital, Rockmed Pharma will accelerate its growth ambitions, driven by new registrations, international expansion and the development of hybrid dossiers.

Further information: www.rockmed.nl/pharma